Background-Atherosclerotic plaque rupture is usually a consequence of inflammatory cell activity within the plaque.
I
nflammation is important in both the pathogenesis and outcome of atherosclerosis. 1 Plaques containing numerous inflammatory cells, in particular macrophages, have a high risk of rupture, whereas those with few inflammatory cells are at lower risk. 2, 3 The current "gold standard" imaging technique for atherosclerosis is x-ray contrast angiography, which provides high-resolution definition of the site and severity of luminal stenoses, but no information about plaque inflammation.
There is a need to quantify plaque inflammation to predict the risk of plaque rupture and to monitor the effects of atheroma-modifying therapies. This is important because recent experimental and clinical studies strongly suggest that hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) promote plaque stability by decreasing plaque macrophage content and activity without substantially reducing plaque size and therefore angiographic appearance. 4 [ 18 F]-fluorodeoxyglucose ( 18 FDG) is a glucose analogue that is taken up by cells in proportion to their metabolic activity. 5 We tested the hypothesis that plaque inflammation could be visualized and quantified non-invasively using 18 FDG-PET in patients with symptomatic carotid artery disease.
Methods

Patient Recruitment
We recruited 8 patients who had experienced a recent carotidterritory transient ischemic attack and had an internal carotid artery stenosis of at least 70%. Patients were excluded if they had either carotid artery occlusion or diabetes. The study protocol was approved by the local ethics committee and the UK Administration of Radioactive Substances Advisory Committee. All patients gave written informed consent.
PET Protocol
PET was carried out using a GE Advance PET scanner (GE Medical Systems). We administered 370 MBq 18 FDG intravenously over 60 seconds. PET images (as 4ϫ5 minute frames) were acquired in 3D mode, at 190 (Ϯ6) minutes after 18 FDG administration. This timepoint was chosen after preliminary dynamic studies indicated that late imaging provided optimal contrast between the 18 FDG concentration in plaque and the main background region, namely blood.
A stiff cervical collar was worn to minimize patient movement. PET images were reconstructed using the 3D reprojection algorithm, 6 with corrections applied for attenuation, dead time, scatter, and random coincidences. Rigid body co-registration with CT was performed, using a combination of fiducial markers and internal anatomical landmarks (spinal cord and muscles of the jaw and neck). This resulted in co-registration typically to within 1 mm in each dimension around the stenosis. To estimate plaque 18 FDG concentration, three-dimensional volumes of interest (VOI) were drawn around the area of stenosis on the contrast CT scan using the Analyze software package (AnalyzeDirect). 7 These regions were then placed onto the co-registered PET images to produce mean 18 FDG concentration values (kBq/mL). The mean VOI size was 148 mm 3 . To determine the plasma 18 FDG concentration up to the scan time (input function), venous blood was sampled throughout the PET study. The estimated net 18 FDG accumulation rate was determined by dividing the mean decay-corrected plaque VOI 18 FDG concentration by the integral of the decay-corrected input function, and is expressed in units of sec Ϫ1 .
CT Protocol
Using a GE Hispeed Advantage CT scanner (GE Medical Systems), helical contrast CT angiograms were acquired from skull base to 3 cm below the level of the carotid bifurcation.
Plaque Histology
After imaging, carotid endarterectomy samples from all 8 patients imaged were fixed and stained with hematoxylin and eosin. Immunohistochemistry was performed using anti-macrophage antibodies (CD68, Dako, Elys, UK).
Plaque Autoradiography
In a separate autoradiographic study, 3 carotid plaques from symptomatic patients were incubated whole with 50 Ci tritiated deoxyglucose (an in vitro analogue of 18 FDG) in 5 mL Medium 199 (Sigma) for 60 minutes at 37°C. Paraffin sections of 5 m thickness were coated with autoradiographic emulsion (LM-1, Amersham), exposed for 6 weeks, developed, and counterstained with hematoxylin and eosin. Control slides were prepared without radioactivity.
Statistical Methods
Results are expressed as meanϮSEM with 95% CI in brackets. The paired t test was used to compare net 18 FDG accumulation rates in symptomatic and asymptomatic carotid plaques in the same patients.
Results
We performed 18 FDG-PET and CT scanning in 8 patients between 48 and 71 years of age (Table) . The median time between symptoms and PET study was 3.5 months, and between PET and carotid endarterectomy was 43 days. In all patients, co-registered PET images acquired around 3 hours revealed 18 FDG accumulation at the site of the symptomatic plaque ( Figure 1) .
Six of the 8 patients had contralateral asymptomatic stenoses ranging from 35% to 75%. A comparison was made between the net 18 FDG accumulation rate in symptomatic plaques and contralateral asymptomatic lesions. In all cases, symptomatic lesions had higher estimated 18 FDG accumulation rates than asymptomatic lesions; the mean symptomatic net accumulation rate was 7.95ϫ10 Ϫ5 Ϯ0.58ϫ10 Ϫ5 sec
Ϫ1
(95% CI: 6.58 to 9.32ϫ10 Ϫ5 ), with a mean difference between symptomatic and asymptomatic of 2.10ϫ10 Ϫ5 Ϯ0.45ϫ 10 Ϫ5 sec Ϫ1 (95% CI 0.94 to 3.26ϫ10 Ϫ5 , Pϭ0.005). The 2 remaining patients had angiographically normal arteries on the asymptomatic side, with no significant uptake of 18 FDG into those vessels; the 18 FDG concentration in a VOI around the carotid bifurcation did not differ significantly from that measured in plasma (wall-to-plasma 18 FDG concentration ratioϭ0.9Ϯ0.1).
Histological examination of the excised symptomatic plaques from all the patients who had undergone imaging revealed heavy macrophage infiltration.
Carotid plaque autoradiography with tritiated deoxyglucose demonstrated uptake in macrophage-rich areas of plaques, predominately at the lipid core/fibrous cap border of the lesions. There was little or no uptake in other areas of the plaques (Figure 2 ). Control sections showed no development of silver grains.
Discussion
Anecdotal reports of "hot spots" in blood vessels of patients at high risk of atherosclerosis undergoing whole body 18 FDG-PET studies, along with a single study in cholesterol-fed rabbits, 8 The values in the "Symptomatic" and "Asymptomatic" columns are the net 18 FDG accumulation rates for symptomatic and asymptomatic plaques, respectively. The absent values in the asymptomatic column represent patients with angiographically normal arteries on the asymptomatic side, in whom there was no significant accumulation of 18 FDG compared to background plasma. The bottom row of the table summarises the overall findings. M indicates male; F, female; R, right; and L, left.
By combining PET and CT imaging, we have confirmed that 18 FDG accumulates in human carotid artery atherosclerotic plaques, with significantly higher uptake in symptomatic lesions than in asymptomatic lesions. Furthermore, we have demonstrated that the majority of deoxyglucose accumulates in macrophage-rich areas of the plaque. These findings suggest that inflammation is present to a greater degree in symptomatic plaques than asymptomatic plaques.
Taken together, these results suggest strongly that 18 FDG-PET may be capable of imaging and potentially quantifying plaque inflammation. This raises the possibility that 18 FDG-PET could be used to predict the risk of future plaque rupture, and therefore to target surgery to high-risk carotid stenoses regardless of angiographic appearance. Perhaps more importantly, it might be used to monitor the effectiveness of systemic atheroma-modifying treatments because it is likely that any measurable effects of treatment on inflammation in carotid atheroma will reflect similar changes in other vascular beds, including the coronary arteries. 9 Before this potential can be realized, further studies are required to determine the precise relationship between 18 FDG uptake, plaque macrophage activity, and risk of plaque rupture, and more macrophage-specific PET ligands will be required to image vessels in metabolically active tissues such as the heart and brain. Although PET has limited spatial resolution (Ϸ 5 mm FWHM for GE Advance), we have demonstrated that co-registration with CT can localize the 18 FDG signal to individual atherosclerotic lesions. Because CT angiography cannot accurately measure plaque volume (because remodeling can accommodate large plaques with little impact on lumen diameter), however, we were unable to apply partial volume correction to our data in this study. We are confident, however, that this will be achievable with high-resolution carotid MRI. 10 In summary, this early study provides the first direct evidence that human atherosclerotic plaque inflammation can be assessed non-invasively by 18 FDG-PET, and paves the way for a new approach to atheroma imaging that reflects the cellular pathology of the disease process rather than its anatomical consequences. Tritiated deoxyglucose autoradiography of symptomatic carotid artery plaque. The larger panel shows typical plaque architecture, whereas the inset shows that silver grains have accumulated at the lipid core/fibrous cap border region, predominately within macrophages. Magnification ϫ10 and ϫ20.
